Meibomian gland disease and reimbursement – Ophthalmology Management

Treatment of meibomian gland dysfunction (MGD) is garnering increased interest, but you need to consider reimbursement issues.

This article answers the following questions:

• What treatments are available for MGD?
• What documentation is required to support treatment?
• How is this treatment reimbursed?
• What CPT code applies: 67700 or 0207T?

• What is meibomian gland dysfunction?

This article was published in Ophthalmology Management’s Coding & Reimbursement column, which is written by Corcoran’s Executive Vice-President, Suzanne Corcoran, COE. To view the entire article in Ophthalmology Management, click on the link below:

http://www.ophthalmologymanagement.com/articleviewer.aspx?articleID=108982